These are routine sell-to-cover transactions for tax obligations upon RSU vesting, not discretionary insider selling. The dollar amounts are immaterial relative to market cap. No bearish signal, monitor for any unplanned open-market sales in future Form 4 filings.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $27.57entry
- T+1 · 5mo ago +1.09%α −0.68% · $27.87
- T+5 · 5mo ago +67.90%α +67.23% · $46.29
- T+20 · 4mo ago +54.62%α +52.84% · $42.63
- T+60 · 2mo ago +65.69%α +62.42% · $45.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two uniQure directors, David D. Meek and Jack Kaye, each filed Form 144 notices on June 11, 2026, signaling intent to sell shares. Meek plans to sell 7,970 shares (~$53,938) and Kaye plans to sell 7,970 shares (~$53,938) plus an additional 2,645 shares (~$79,384) from a prior vesting, for a combined ~$187,260. The sales are tied to restricted stock unit vesting and settlement of equity awards, not discretionary insider conviction selling.
Key Facts
- Two directors (David D. Meek and Jack Kaye) filed Form 144 on June 11, 2026
- Meek intends to sell 7,970 ordinary shares (~$53,938)
- Kaye intends to sell 7,970 ordinary shares (~$53,938) plus 2,645 shares (~$79,384) from a prior vesting
- All sales are attributed to restricted stock unit vesting and settlement of equity awards
- Combined proposed sale value is approximately $187,260
- Market cap is $1.7B; proposed sales represent ~0.01% of market cap
Financial Impact
Combined ~$187,260 in proposed insider sales, representing ~0.01% of $1.7B market cap
Risk Factors
- If additional directors or executives file unexpected Form 144s in the coming weeks, it could signal broader insider sentiment shift
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (QURE), Batch item 1 | 0001973379-26-000229 |
| Document: 0001973379-26-000229-index.html | 0001973379-26-000228 |
| Document: 0001973379-26-000229.txt | 0001973379-26-000229 |
| 144 Filing (QURE), Batch item 4 | 0001973379-26-000228 |
| Document: 0001973379-26-000228-index.html | 0001973379-26-000229 |
| Document: 0001973379-26-000228.txt | 0001973379-26-000229 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers